10-Q · May 15, 2026
NanoViricides, Inc. continues to experience significant operating losses as it advances its antiviral drug NV-387, which just completed a Phase I clinical trial. The balance sheet shows improved cash reserves, yet…
Earnings analysis · 10-K
NNVC earnings analysis
Filed September 28, 2026 · Our reading of the company's report
The latest report
NanoViricides remains a pre-revenue, clinical-stage biotechnology company focused on advancing NV-387 and a broader licensed antiviral pipeline, with the main operating focus shifting toward Mpox and Ebola development.…
Read full summary
NanoViricides remains a pre-revenue, clinical-stage biotechnology company focused on advancing NV-387 and a broader licensed antiviral pipeline, with the main operating focus shifting toward Mpox and Ebola development. Fiscal 2026 showed improved losses and lower R&D and G&A spending, but the Company generated no revenue, used $7.696 million in operating cash, and reported substantial doubt about its ability to continue as a going concern. The investment case is therefore dominated by clinical execution and access to additional financing, with significant dilution and new Ebola trial spending adding to the risk profile.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.41
- Segment
- Life science: $0 revenue; the Company operates as one reportable segment focused on clinical and preclinical antiviral drug candidates.
What stood out
-
NV-387 advancing toward Phase II
NanoViricides completed Phase Ia/Ib human safety and tolerability work for NV-387 and is advancing the candidate toward Phase II programs for Mpox, Ebola, Viral ARI/SARI, and potentially Measles. The filing identifies these programs as key milestones, although no product has yet been commercialized.
-
R&D focused on Mpox development
R&D spending was $4.708 million in fiscal 2026, down from $5.549 million in fiscal 2025. The largest program allocation shifted toward Smallpox/Mpox, which increased to $1.903 million from $0.400 million.
-
Loss and EPS trajectory improved
The net loss improved to $8.219 million, or $0.41 per diluted share, from $9.467 million, or $0.63 per diluted share, in the prior year. Operating expenses declined to $8.306 million from $9.592 million, driven by lower R&D and G&A spending.
-
Financing increased year-end liquidity
The Company raised $9.016 million of net financing proceeds during fiscal 2026, consisting of $1.909 million from ATM sales and $7.107 million from registered direct offerings. Cash increased to $2.794 million at June 30, 2026 from $1.559 million a year earlier.
-
Owned cGMP-capable infrastructure
The Company owns an approximately 18,000-square-foot office, laboratory, and cGMP-capable manufacturing facility with no outstanding debt or mortgage. Capital expenditures were limited to $84,317 in fiscal 2026.
-
Broad licensed antiviral platform
The strategy centers on a worldwide exclusive license from TheraCour for a host-mimicry nanomedicine platform and broad antiviral pipeline. The Company states that coronavirus patent applications could provide potential protection into at least 2041, and possibly as late as 2043 with extensions.
What to watch
-
Funding gap and going-concern risk
The filing states that substantial doubt exists about the Company’s ability to continue as a going concern. Cash was approximately $2.8 million at June 30, 2026, while management’s July 2026-October 2027 budget requires approximately $12.3 million; even including approximately $3.4 million raised after year-end and a $3 million line of credit, planned operations are not funded for at least 12 months from the filing date.
-
Accelerating dilution from financing
Equity financing materially increased potential dilution: common shares outstanding rose from 16,606,832 at June 30, 2025 to 23,008,308 at June 30, 2026, while 8,480,768 warrants were outstanding at year-end. The Company also has 150 million authorized common shares and states it may need to sell additional equity to fund operations.
-
New Ebola trial cash commitment
The Ebola program creates a new near-term cash requirement after year-end. Following regulatory approval on or about August 4, 2026, the Company had incurred and paid approximately $923,000 through September 28, 2026 and estimates the Phase II trial will cost approximately $2.5 million to $3.0 million.
-
Related-party and license dependence
The Company is highly dependent on TheraCour, which is controlled by Chairman and President Anil Diwan, who owns approximately 90% of TheraCour. NanoViricides incurred approximately $1.995 million of TheraCour development fees in fiscal 2026 and owed TheraCour approximately $828,577 at June 30, 2026.
-
Near-term patent-expiration exposure
Several licensed patents expire between 2026 and 2028, and the filing states there is no assurance that additional patent protection will be granted or remain enforceable. Loss of this protection could expose product candidates to competition before commercialization.
Management's outlook
No numeric annual revenue or EPS guidance was provided. Management disclosed a planned cash expenditure budget of approximately $12.3 million for July 2026 through October 2027, including $8.2 million for R&D and $4.1 million for G&A; it also estimates the Ebola Phase II trial will cost approximately $2.5 million to $3.0 million.
Earlier filings 4
10-Q · February 17, 2026
NanoViricides remains a pre-revenue clinical-stage company. For the quarter ended December 31, 2025 the company reported a net loss of $2,220,719 (EPS -$0.11) and operating expenses of $2,233,174; cash increased to…
10-Q · November 14, 2025
NanoViricides reported a narrower quarterly net loss of $1,785,058 (EPS -$0.10) for the three months ended September 30, 2025 versus a net loss of $3,126,811 (EPS -$0.23) in the year‑ago quarter. The company remains…
10-Q · May 15, 2025
NanoViricides reported a quarterly net loss of $2,216,783 (EPS -$0.14) for the three months ended March 31, 2025 versus a net loss of $1,854,476 (EPS -$0.16) in the year‑ago quarter; the company still reports no…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.